News
Novo Nordisk Fonden: New international research center to drive future stem cell-derived medicines
Stem cell medicine is delivering hope for new treatments across…
Novo Nordisk Foundation – New international research center to drive future stem cell-derived medicines
A grant from the Novo Nordisk Foundation of up to 300 million…
FDA grants Calliditas Therapeutics Accelerated Approval of TARPEYO™ (budesonide) to Reduce Proteinuria in IgA Nephropathy
TARPEYO (budesonide) delayed release capsules is the first…
2021 and beyond with Destiny Pharma’s CEO, Neil Clark & CFO Shaun Claydon
Management of Destiny Pharma (DEST), the AIM listed infection…
ViCentra closes EUR 65M (USD 74M) Series C funding to expand the footprint of world’s smallest insulin pump across Europe
New investor, Partners in Equity – joins existing investors…
Depixus Raises USD 35.4M in Series A Financing
The financing will support development of a commercial instrument…
Biocomposites year of international growth and product advancement
Expansion into new geographies and enhanced approval for STIMULAN…
Egetis intends to submit a marketing authorisation application for Emcitate® to the European Medicines Agency based on existing clinical data
Egetis concludes, based on recent regulatory interactions,…
EXACT Therapeutics AS to present at DNB Nordic Healthcare Conference on 16th December 2021
OSLO/LONDON: 13 DECEMBER, 2021: EXACT Therapeutics AS (“EXACT-Tx”,…
Eir Ventures Closes Life Science Venture Fund at EUR122 million
New Nordic fund focused on high-impact medical innovation
Nine…
eTheRNA immunotherapies conference attendance from December 2021 to March 2022
eTheRNA immunotherapies NV (‘eTheRNA’), a private clinical-stage…
Merck KGaA, Darmstadt, Germany, Expands Corporate Venture Fund M Ventures with a New Investment of € 600 Million
Merck KGaA, Darmstadt, Germany, a leading science and technology…
Biocomposites Signs Distribution Agreement with NuVasive Specialized Orthopedics to supply STIMULAN® in Germany
STIMULAN® is the first and only calcium matrix approved as an…
ISA to present key learnings for cancer vaccine development at the ESMO Immuno-Oncology Congress
Oegstgeest, December 7, 2021 – ISA’s very own Chief Scientific…
ATP Launches Adendra Therapeutics, a New Kind of Immunotherapy Company Deploying Novel Insights into Dendritic Cell Biology, with $53M Series A
Co-founded with renowned immunologist Professor Caetano Reis…
Exact Therapeutics AS Appoints Prominent Ultrasound And Healthcare Expert To Its Board Of Directors
Underscores the Company’s ambition to harness the power of…
Leucid Bio and Lonza Enter Strategic Collaboration to Leverage the Cocoon® Platform for Automated Manufacturing of Personalised CAR T-Cells
Leucid will work with Lonza on the Cocoon® Platform for…
ONA Therapeutics Appoints Dr Michel Detheux as Independent Chair to Board of Directors
Seasoned biotech executive with a wealth of experience and a…
Adcendo Further Strengthens Management Team and Scientific Advisory Board with Appointment of International ADC Leaders
Building the team with experienced biotech experts and renowned…
We’d love to hear from you.
For more information about Optimum Strategic Communications, please get in touch.
We are specialists with an indepth understanding of how to communicate complex science to investors and corporate stakeholders. We help companies on their journey as they grow and have been trusted by hundreds of clients from around the world, both public and private, large and small.
Locations
- London
- Amsterdam
- Stockholm
- Zurich
- New York
